Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease
Aya Ozaki(Sakai Municipal Hospital), Cynthia A. Jackevicius(Western University), Karen Tu(Western University), Peter C. Austin(University of Toronto), Gillian L. Booth(University of Toronto), Alice Chong(Sunnybrook Health Science Centre), Jacob A. Udell(University Health Network), Jiming Fang, Clare Atzema(Cancer Care Ontario), Thérèse A. Stukel(University of Toronto), David Naimark(Sunnybrook Health Science Centre), Dennis T. Ko(University of Toronto)
Cited by 48
Related Papers
Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection
|New England Journal of Medicine|2018|1.2k
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Trajectory of Performance Status and Symptom Scores for Patients With Cancer During the Last Six Months of Life
|Journal of Clinical Oncology|2011|464